1715. A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Trial to Examine the Effects of DAS181 in Immunocompromised (IC) Patients With Parainfluenza Virus (PIV) Lower Respiratory Tract Infection (LRTI) on Supplemental Oxygen (SO)

BACKGROUND: PIV infections are an important cause of morbidity and mortality in IC patients. DAS181, a sialidase fusion protein, has demonstrated activity in preclinical and clinical studies. METHODS: Adult IC patients diagnosed with PIV LRTI on chest imaging and required SO ≥ 2 L/minute were random...

Descripción completa

Detalles Bibliográficos
Autores principales: Chemaly, Roy F, Moss, Ronald, Marty, Francisco M, Wolfe, Cameron R, Lawrence, Steven J, Dadwal, Sanjeet, Soave, Rosemary, Hwang, Jimmy, Hawley, Stephen, Routh, Rebecca, Ho, Jennifer, Wang, George, Chang, Nancy, Boeckh, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252525/
http://dx.doi.org/10.1093/ofid/ofy209.121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252525/
http://dx.doi.org/10.1093/ofid/ofy209.121

Ejemplares similares